Young Survivors at Kantonsspital Aarau, Switzerland
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorKantonsspital Aarau
About this trial
The Young Survivors at Kantonsspital Aarau project assesses the prevalence and severity of late effects in survivors of childhood and adolescent cancer according to the modified CTCAE criteria prospectively. The clinical data are generated during regular follow-up care visits, the collection starts directly after completion of treatment and is longitudinally.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
have been treated for cancer in the Division of Oncology-Hematology, Department of Pediatrics, at the Kantonsspital Aarau,
have been diagnosed at age 0-18 years,
are still in regular follow-up care at the Kantonsspital Aarau,
have finished cancer treatment and entered follow-up care, and
Disqualifiers
are in a palliative situation or
have not given consent for further use of medical data
Trial population
The study population includes all children, adolescents and adults who have been treated for cancer in the Division of Oncology-Hematology, Department of Pediatrics, at the Kantonsspital Aarau and who have completed their treatment and have entered follow-up care.
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Physical examination, diagnostic tests, laboratory tests
Other interventionPhysical examination, diagnostic tests (e.g. lung function test, echocardiography, audiometry), and laboratory tests (e.g. kidney parameter, hormonal levels) depend on examined organ system.
Personal history
Other interventionPersonal history on diagnosis, treatment, and socioeconomic factors
Treatment groups
300 Participants
are divided into 2 treatment groupsGroup A: Group A (largest part of the cohort)2 interventions
Group B: Group B (very small part of the cohort)2 interventions
Trial outcomes
Primary outcomes
1
Test results to assess organ-specific late effects (example of cardiac health)
Number of survivors with heart valve disorder, hypertension, left ventricular systolic dysfunction when at risk for cardiac late effects
Time frame
at recruitment or 2016 onwards, whichever comes firstSecondary outcomes
1
Test results to assess organ-specific late effects (example of cardiac health)
Number of survivors with heart valve disorder, hypertension, left ventricular systolic dysfunction etc. when at risk for cardiac late effects
Time frame
annually from recruitment or 2016 onwards, whichever comes first2
Sociodemographic and socioeconomic characteristics (e.g. age at clinical examination, gender, education or working situation, living situation)
Time frame
annually from recruitment or 2016 onwards, whichever comes first3
Comorbidities (e.g. arterial hypertension, obesity) as risk factors for late effects
Time frame
annually from recruitment or 2016 onwards, whichever comes first4
Diagnosis-related data (e.g. age at diagnosis, diagnosis, disease stage, treatment protocol)
Time frame
at recruitment or 2016 onwards, whichever comes firstSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov